# PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

> **NCT00335868** · PHASE2 · UNKNOWN · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 16 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** danusertib
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00335868
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2013-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335868, "PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00335868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*